department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Vtama · pharmadog

pharmadog
drugs
Vtama

drug

patient view →

tapinarof

Marketedupdated 2mo ago

by Dermavant Sciences Inc

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Vtama

generic

tapinarof

indication

Atopic Dermatitis (Atopic Eczema)

phase

marketed

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

May 23, 2027

317 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (12)

Dec 18, 2039method-of-use (U-4048)US 12569453
Nov 13, 2039method-of-use (U-4048)US 11497718
Nov 13, 2039method-of-use (U-2625)US 11590088
Nov 13, 2039method-of-use (U-4048)US 11938099
Nov 13, 2038compositionUS 10647649
Nov 13, 2038compositionUS 11597692
May 23, 2036formulationUS 10195160
May 19, 2036method-of-use (U-2625)US 10426743
May 19, 2036formulationUS 11458108
May 19, 2036method-of-use (U-2625)US 11612573
May 19, 2036formulationUS 11617724
May 19, 2036formulationUS 11622945

FDA exclusivities (2)

Dec 12, 2027I-956Indication (3y)1.4y
May 23, 2027NCENew Chemical Entity (5y)317d

Data sources

ClinicalTrials.gov

last refreshed 2h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Trials studying tapinarof

phase3A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitisrecruitingn=180
phase1A Study Comparing Tapinarof Cream 1% and Vtama® Cream 1% in the Treatment of Plaque Psoriasis.completedn=575
phase3Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjectsactive not recruitingn=58
phase1Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancernot yet recruitingn=30
phase2Study to Evaluate the Safety and Efficacy of Tapinarof in Adults With Palmoplantar Keratodermarecruitingn=6
phase3Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant)enrolling by invitationn=40
phase3Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasiscompletedn=560
phase2Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitiscompletedn=36

more trials →